These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

356 related items for PubMed ID: 28104251

  • 1. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: A double-blind, randomized controlled trial and open-label pharmacokinetic study.
    Saida T, Kira JI, Kishida S, Yamamura T, Sudo Y, Ogiwara K, Tibung JT, Lucas N, Subramanyam M, Natalizumab Trial Principal Investigators.
    Mult Scler Relat Disord; 2017 Jan; 11():25-31. PubMed ID: 28104251
    [Abstract] [Full Text] [Related]

  • 2. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
    Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N, NOVA study investigators.
    Lancet Neurol; 2022 Jul; 21(7):608-619. PubMed ID: 35483387
    [Abstract] [Full Text] [Related]

  • 3. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
    Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D, ASCEND investigators.
    Lancet Neurol; 2018 May; 17(5):405-415. PubMed ID: 29545067
    [Abstract] [Full Text] [Related]

  • 4. Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY).
    Cohan SL, Moses H, Calkwood J, Tornatore C, LaGanke C, Smoot KE, Meka V, Okwuokenye M, Hotermans C, Mendoza JP, Mann MK, Meltzer LA.
    Mult Scler Relat Disord; 2018 May; 22():27-34. PubMed ID: 29524759
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial.
    Hemmer B, Wiendl H, Roth K, Wessels H, Höfler J, Hornuss C, Liedert B, Selmaj K.
    JAMA Neurol; 2023 Mar 01; 80(3):298-307. PubMed ID: 36689214
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics and Pharmacodynamics of Natalizumab 6-Week Dosing vs Continued 4-Week Dosing for Relapsing-Remitting Multiple Sclerosis.
    Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter GR, Giovannoni G, Killestein J, Wiendl H, Li K, Dsilva L, Toukam M, Ferber K, Sohn J, Engelman H, Lasky T.
    Neurol Neuroimmunol Neuroinflamm; 2024 Dec 01; 11(6):e200321. PubMed ID: 39393045
    [Abstract] [Full Text] [Related]

  • 7. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW, CHOICE investigators.
    Lancet Neurol; 2010 Apr 01; 9(4):381-90. PubMed ID: 20163990
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS.
    Ghezzi A, Comi G, Grimaldi LM, Moiola L, Pozzilli C, Fantaccini S, Gallo P.
    Neurol Neuroimmunol Neuroinflamm; 2019 Sep 01; 6(5):e591. PubMed ID: 31355324
    [Abstract] [Full Text] [Related]

  • 9. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis.
    Arnold DL, Calabresi PA, Kieseier BC, Sheikh SI, Deykin A, Zhu Y, Liu S, You X, Sperling B, Hung S.
    BMC Neurol; 2014 Dec 31; 14():240. PubMed ID: 25551571
    [Abstract] [Full Text] [Related]

  • 10. A Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses.
    O'Connor PW, Li D, Freedman MS, Bar-Or A, Rice GP, Confavreux C, Paty DW, Stewart JA, Scheyer R, Teriflunomide Multiple Sclerosis Trial Group, University of British Columbia MS/MRI Research Group.
    Neurology; 2006 Mar 28; 66(6):894-900. PubMed ID: 16567708
    [Abstract] [Full Text] [Related]

  • 11. A Randomized Trial Evaluating Various Administration Routes of Natalizumab in Multiple Sclerosis.
    Plavina T, Fox EJ, Lucas N, Muralidharan KK, Mikol D.
    J Clin Pharmacol; 2016 Oct 28; 56(10):1254-62. PubMed ID: 26835603
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
    Putzki N, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, Klawe C, Maschke M, Tettenborn B, Limmroth V.
    Eur J Neurol; 2010 Jan 28; 17(1):31-7. PubMed ID: 19614963
    [Abstract] [Full Text] [Related]

  • 13. A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis - Rationale and design.
    Curtin F, Porchet H, Glanzman R, Schneble HM, Vidal V, Audoli-Inthavong ML, Lambert E, Hartung HP.
    Mult Scler Relat Disord; 2016 Sep 28; 9():95-100. PubMed ID: 27645352
    [Abstract] [Full Text] [Related]

  • 14. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.
    Mult Scler; 2010 Jul 28; 16(7):848-54. PubMed ID: 20488825
    [Abstract] [Full Text] [Related]

  • 15. Natalizumab for Achieving Relapse-Free, T1 Gadolinium-Enhancing-Lesion-Free, and T2 Lesion-Free Status in Japanese Multiple Sclerosis Patients: A Phase 2 Trial Subanalysis.
    Saida T, Kira JI, Kishida S, Yamamura T, Ohtsuka N, Dong Q, Tibung JT.
    Neurol Ther; 2017 Jun 28; 6(1):153-159. PubMed ID: 28078634
    [Abstract] [Full Text] [Related]

  • 16. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
    Trojano M, Butzkueven H, Kappos L, Wiendl H, Spelman T, Pellegrini F, Chen Y, Dong Q, Koendgen H, Belachew S, Tysabri® Observational Program (TOP) Investigators.
    Mult Scler Relat Disord; 2018 Aug 28; 24():11-19. PubMed ID: 29860197
    [Abstract] [Full Text] [Related]

  • 17. 72-Week Safety and Tolerability of Dimethyl Fumarate in Japanese Patients with Relapsing-remitting Multiple Sclerosis: Analysis of the Randomised, Double Blind, Placebo-Controlled, Phase III APEX Study and its Open-Label Extension.
    Ochi H, Niino M, Onizuka Y, Hiramatsu K, Hase M, Yun J, Matta A, Torii S.
    Adv Ther; 2018 Oct 28; 35(10):1598-1611. PubMed ID: 30206820
    [Abstract] [Full Text] [Related]

  • 18. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
    Perumal J, Fox RJ, Balabanov R, Balcer LJ, Galetta S, Makh S, Santra S, Hotermans C, Lee L.
    BMC Neurol; 2019 Jun 08; 19(1):116. PubMed ID: 31176355
    [Abstract] [Full Text] [Related]

  • 19. Are natalizumab and fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study.
    Gajofatto A, Bianchi MR, Deotto L, Benedetti MD.
    Eur Neurol; 2014 Jun 08; 72(3-4):173-80. PubMed ID: 25226868
    [Abstract] [Full Text] [Related]

  • 20. Natalizumab Treatment for Relapsing-Remitting Multiple Sclerosis: The Experience From Saudi Arabia.
    Algahtani H, Shirah B, Abobaker H, Alghanaim N, Kamel F.
    Clin Neuropharmacol; 2018 Jun 08; 41(6):199-201. PubMed ID: 30234558
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.